Nestlé Gets Serious With Seres Deal
The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.
Candid conversations with C-suite leaders.
More from Deal-Making
- • By
<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>
- • By
China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”
- • By
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
- • By
An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.